Reaction
Bronchial Carcinoma reporting signals
As of the last recalculation, Bronchial Carcinoma appears in 783 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is TOLVAPTAN (PRR 24.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tolvaptan | 13 | 24.2 | 24.2 |
| Crizotinib | 11 | 23.3 | 23.3 |
| Baricitinib | 8 | 22.3 | 22.3 |
| Erlotinib Hydrochloride | 6 | 12.8 | 12.8 |
| Brinzolamide | 4 | 12.3 | 12.3 |
| Pemetrexed | 9 | 11.3 | 11.3 |
| Pemetrexed Disodium | 15 | 10.7 | 10.7 |
| Durvalumab | 6 | 7.9 | 7.9 |
| Osimertinib | 9 | 7.5 | 7.5 |
| Ranibizumab | 7 | 7.1 | 7.1 |